Formulation and Evaluation of Extended-Release Tablets of Ranolazine

Abstract

The purpose of pharmaceutical formulations such as extended-release tablets is to allow the gradual and prolonged absorption of medications into the body. Compared to immediate-release formulations, they provide a number of benefits, such as less dosage frequency, less variation in drug concentration, better patient compliance, and maybe fewer adverse effects.This project aims to develop and test Ranolazine Extended Release Matrix tablets that can prolong the drug's release profile up to 24 hours. The results will be compared to the invitro release profile of the commercially available formulation. twelve formulations (F1-F12) were prepared with the utilization of various polymers and then compared with the innovator's formulation. The formulation (F12) consisting of HPMC K100M, Stearic acid, and Carbopol 974p exhibited a drug release of 99% within 24 hours, which is similar to the innovator product and is regarded as the optimized formulation. The optimized formulation was determined to have a similarity factor of 64.3.